PMV Pharmaceuticals Announces $30 Million Raised In Series A Financing

DOYLESTOWN, Pa.--(BUSINESS WIRE)--PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53 targeted small molecule drugs for the treatment of cancer, announced today the completion of a $30 million Series A financing. This financing is being led by OrbiMed, with participation by Osage University Partners, and supported by founding investor, InterWest Partners.

Help employers find you! Check out all the jobs and post your resume.